Abby Hardy, Author at BioTuesdays

Markets

Stifel resumes coverage of Genocea Biosciences at buy; PT $13

Stifel resumed coverage of Genocea Biosciences (NASDAQ:GHCA) with a “buy” rating and $13 price target. The stock closed at $3.83 on July 5.

July 8, 2019

Executive Moves

Zenabis’ expansion welcomed by Stellarton residents

Zenabis Global’s (TSX:ZENA) expansion in Stellarton, Nova Scotia, is good news for local residents, as the company is looking to fill several positions at that particular facility this summer.

July 4, 2019

Developments

Ovid Therapeutics OV101 granted orphan designation in Europe

Ovid Therapeutics (NASDAQ: PTI) reported that, following a positive opinion from the European Medicines Agency, the European Commission granted OV101 orphan drug designation for the treatment of Angelman syndrome.

July 3, 2019

Markets

HCW starts Principia Biopharma at buy; PT $55

H.C. Wainwright initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $55 price target. The stock closed at $37.61, up $4.42, on July 1.

July 2, 2019

Developments

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

vTv Therapeutics (NASDAQ:VTVT) initiated a Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D).

June 29, 2019

Developments

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Arcturus Therapeutics (NASDAQ:ARCT) received FDA orphan drug designation for ARCT-810 for the treatment of ornithine transcarbamylase (OTC) deficiency.

June 29, 2019

Developments

Zogenix reaches agreement with FDA for FINTEPLA NDA resubmission

Following a Type A meeting with the FDA, Zogenix (NASDAQ:ZGNX) reported that it plans to resubmit its NDA for FINTEPLA for the treatment of seizures associated with Dravet syndrome.

June 27, 2019

Markets

SVB Leerink cuts Aclaris Therapeutics to MP; PT to $4 from $13

SVB Leerink downgraded Aclaris Therapeutics (NASDAQ:ACRS) to “market perform” from “outperform” and slashed its price target to $4 from $13 after the failure of the company’s topical treatment for alopecia areata, an...

June 27, 2019

Developments

Inovio Pharma completes enrollment for HPV-related cervical pre-cancer trial

Inovio Pharmaceuticals (NASDAQ:INO) reached target enrollment of 198 women for its pivotal Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia caused by human papillomavirus (HPV).

June 26, 2019

Executive Moves

BioSig names Samuel Navarro to board

BioSig Technologies (NASDAQ:BSGM) appointed Samuel Navarro as an independent director.

June 25, 2019

Author - Abby Hardy

Stifel resumes coverage of Genocea Biosciences at buy; PT $13

Zenabis’ expansion welcomed by Stellarton residents

Ovid Therapeutics OV101 granted orphan designation in Europe

HCW starts Principia Biopharma at buy; PT $55

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Zogenix reaches agreement with FDA for FINTEPLA NDA resubmission

SVB Leerink cuts Aclaris Therapeutics to MP; PT to $4 from $13

Inovio Pharma completes enrollment for HPV-related cervical pre-cancer trial

BioSig names Samuel Navarro to board

Subscribe